LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website: https://business.uoregon.edu/centers/lce

Clinical Trials

Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

Phase 3

Completed

Conditions: Chronic Pain

Interventions: Drug: Placebo
Drug: Ketamine

First Posted Date: 2016-09-30

Last Posted Date: 2021-04-15

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 106

Registration Number: NCT02920528

Locations: 🇺🇸
Emergency Department, Harbor-UCLA Medical Center, Torrance, California, United States

MyoVista Measurements in Patients With Atherosclerosis and CAD

Completed

Conditions: Atherosclerosis
Coronary Artery Disease (CAD)

First Posted Date: 2016-08-19

Last Posted Date: 2024-10-14

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 200

Registration Number: NCT02873052

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Stiolto Respimat
Drug: Placebo Respimat

First Posted Date: 2016-07-27

Last Posted Date: 2020-08-06

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 14

Registration Number: NCT02845752

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Effective Approaches & Strategies to Ease Off Nasal CPAP In Preterm Infants

Not Applicable

Completed

Conditions: BronchoPulmonary Dysplasia
Neonatal Respiratory Distress Syndrome
Extremely Low Birth Weight Infant (ELBW)

Interventions: Device: NCPAP

First Posted Date: 2016-06-30

Last Posted Date: 2021-12-10

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT02819050

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

Phase 3

Conditions: Migraine Disorders

Interventions: Drug: Prochlorperazine

First Posted Date: 2016-05-23

Last Posted Date: 2018-01-05

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT02779959

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis

Not Applicable

Not yet recruiting

Conditions: Arthritis, Rheumatoid

Interventions: Behavioral: Rheumatoid arthritis educational booklet
Behavioral: Monthly healthcare coordinator calls
Behavioral: Multidisciplinary rheumatologic care
Behavioral: Nurse education and monthly calls
Behavioral: Technology-based symptom monitoring and reporting

First Posted Date: 2016-03-28

Last Posted Date: 2024-10-09

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 150

Registration Number: NCT02720874

Locations: 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States

ACTIMMUNE in Intermediate Osteopetrosis

Phase 2

Completed

Conditions: Osteopetrosis

Interventions: Drug: Interferon gamma-1b

First Posted Date: 2016-01-28

Last Posted Date: 2024-10-22

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 5

Registration Number: NCT02666768

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization

Phase 2

Completed

Conditions: S. Aureus Oropharyngeal Colonization

Interventions: Drug: Saline Placebo
Drug: Chlorhexidine gluconate

First Posted Date: 2015-10-28

Last Posted Date: 2020-12-29

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 67

Registration Number: NCT02589067

Locations: 🇺🇸
Los Angeles BioMedical Research Institute (LA BioMed), Torrance, California, United States

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Phase 1

Completed

Conditions: Mucopolysaccharidosis Type VI
Mucopolysaccharidosis Type I
Mucopolysaccharidosis Type II

Interventions: Drug: Adalimumab
Other: Placebo

First Posted Date: 2015-05-07

Last Posted Date: 2017-09-15

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 2

Registration Number: NCT02437253

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Safety of Nitroglycerin for Field Treatment of STEMI

Completed

Conditions: Myocardial Infarction

First Posted Date: 2015-04-02

Last Posted Date: 2017-08-25

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 940

Registration Number: NCT02407002

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy